Navigation Links
Concept in Medical Technology

Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer

MONTREAL, Feb. 9 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two phase 1 studies in healthy volunteers and preclinical studies on SPI-452, a novel pharmacokinetic enhancer (PKE) with no inherent antiviral activity. Pharmacokinetic enhancers increase drug level...

Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository

JERUSALEM, Israel, February 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, announced today that it has concluded a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary tec...

Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements

CHICAGO and REGENSBURG, Germany, June 2 /PRNewswire/ -- "A two-year survival rate of more than 80 percent in recurrent or refractory anaplastic astrocytoma suggests a breakthrough in this devastating disease by targeted therapy," commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinatin...

ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment

Top-line Data Show Significant Improvements With ROX-828 In Migraine Pain And Related Symptoms For Up to 48 Hours Vs. Placebo MENLO PARK, Calif., April 28 /PRNewswire/ -- ROXRO PHARMA, Inc. today announced positive top-line data from a clinical study of the company's novel investigatio...

Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology

CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that additional preclinical in vivo studies using dogs further demonstrate that its proprietary eligen(R) technology enhances the absorption of oral B12. These data confirm in a...

Immunosyn Releases Wound Healing Photographs From the First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019

LA JOLLA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) received permission from Argyll Biotechnologies, LLC to release before and after wound healing photographs resulting from subcutaneous injections of the biopharmaceutical SF-1019 from the first...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

SOPHIA ANTIPOLIS, France, Nov. 20 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced that TOPIGEN Pharmaceuticals Inc. has dosed the first patients in a phase 2 proof of concept study for TPI 1020 in Chronic Obstructive Pulmonary Disease (COPD) - see TOPIGEN press release attached. Thi...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

- Company plans initiation of clinical studies; Data to be presented at AACR - BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of c...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc. (NASDAQ: POZN), today announced top-line results of its "Safer Aspirin" PA 325 proof-of-concept study conducted during the fourth quarter of 2006. PA 325 is a patented formulation of 325mg of aspirin surrounded by a 20mg coating of an imm...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today positive results from pre-clinical studies of its TPM-02 dermal drug delivery technology formulated with retinoic acid, a leading topical treatment for severe acne and an active ingredien...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an exist...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an exist...

S.C. Medical Home Pilot for Diabetes Enrolls 1,110

...nt centered medical homes integrate quality improvement, coordinated care management and patient educational services into primary care practices. The concept places the primary care doctor in charge of a team that can include social workers, pharmacists, wellness coordinators, nurses, disease managers, cert...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an exist...

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

...ent to ensuring that the VerifyNow System is shown to be an integral tool in optimizing the use of antiplatelet therapy." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. Also being demonstrated with increased frequency is the question of whe...

Alfacell Provides Shareholder Update

... Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations o...

Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat

...nix, Arizona, announced today a collaboration agreement for the development and commercialization of advanced germplasm and traits in wheat. The concept of the collaboration is to couple Dow AgroSciences' expertise in seeds and traits with W3's proprietary wheat germplasm and robust breeding capabiliti...

AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis

...ted to report in the first quarter of 2010. Additional open label experience with AIMSPRO, over an extended period, has led Daval to consider Proof of concept studies in Adhesive Arachnoiditis, treatment resistant Myasthenia Gravis and Psoriatic arthritis. AIMSPRO is listed on the Export Only section ...

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

...tide Linaclotide is a first-in-class compound in Phase 3 clinical development for the treatment of IBSC and CC. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linacloti...

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

...aged others to market coated balloons, but without the Paccocath technology, none have proven clinical science benefits. According to Dr. Ansel, "The concept of drug eluting balloons is very attractive, but there may be much more to creating a clinical effect than just putting a drug onto an angioplasty bal...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

... addition to the upfront and milestone payments, OBT will receive double-digit royalties on sales of any product that it develops to clinical proof of concept and single-digit royalties on worldwide sales of marketed GSK antibody products aimed at OBT targets. Furthermore, OBT may opt to carry forward the OB...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...A and 2.5% for placebo. Please see accompanying full prescribing information or visit www.Cimzia.com . About OXO Founded in 1990 on the concept of Universal Design, OXO's mission is to create consumer household products that ease the tasks of everyday life for the widest range of users possibl...

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

...introduced in the scholarly press, in hopes of drawing bigger grant awards and perhaps the interest of a company willing to spend the money to convert concept into product. Researchers sometimes took their work off campus, establishing their own companies on the side. But the Bayh-Dole Act passed in 198...

InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients

...ure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world. About InspireMD InspireMD Ltd. is an inn...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

... a first-in-class compound in Phase 3 clinical development for the treatment of IBS-C and chronic constipation (CC). Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linacloti...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

... usual therapeutic doses prednisolone acetate and cyclosporine A, to retain the efficacy of a very potent steroid with an improved safety profile. The concept was first discovered and patented by CombinatoRx (Nasdaq: CRXX ) and Fovea holds an exclusive worldwide license to this intellectual property for op...

VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis

...nvestigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic patients later this year. "VTX-1463 is the first selective TLR8 compound to reach the clinic for allergy," said Micha...

Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis

...nificant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101. The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, sur...

Nation's Laboratory Response Network Marks First Decade of Protecting Public Health

...us anthraci s , the index case for the anthrax events of 2001, in a clinical specimen," remembers APHL Executive Director Scott Becker. "That day the concept of a national, rapid response laboratory network proved its worth." In subsequent years, the LRN's portfolio expanded in response to outbreaks of...

Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients

... treat Hepatitis-C The Company's ongoing Phase I/II clinical trial for EPODURE in anemic patients continues to demonstrate proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for up to six months or more, EPODURE Biopumps are already maintai...

Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients

...the Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study should NOT lead to an abandonment of the concept of good glucose management in the hospital setting. Uncontrolled high blood glucose can lead to serious problems for hospitalized patients, such as d...

Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes

... --Study will evaluate proof of concept for company's first-in-class SERM designed to relieve vasomotor symptoms without side effects associated with hormone therapy-- CAMBRIDGE, Mass.,...

InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation

...ulate the involvement of scientists worldwide in solving global scientific challenges, via an online marketplace for problems and their solutions. The concept of "open innovation" addresses the research challenges that organizations face, by using external expertise to solve problems and drive development of...

Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor

... INDIANAPOLIS, March 17 /PRNewswire/ -- Semafore Pharmaceuticals, Inc. announced today that it has achieved proof of concept in its CRIMP (Control Resulting from Inhibiting Multiple Pathways) kinase platform by designing a small molecule that was demonstrated to inhibit memb...

Freezing Prostate Cancer Does a Man's Body Good

...y remains confined to the prostate gland, said Onik. Growing evidence of overdetection and overtreatment in many men with low-risk tumors has led to a concept in the medical community of "watchful waiting" or observing a man's disease progression prior to initiating treatment. Many patients, however, feel un...

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds

... how bioengineered skin plays a critical role in this procedure. "The concept of using bioengineered skin to heal difficult wounds, such as leg and foot ...ears remained healed and free of pain from this procedure. Importantly, the concept of 'instructing' stem cells with other interventions or biological agents i...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

... of a mode of action in common with other compounds, referred to as metal protein attenuating compounds, which have begun to show promising proof of concept in human clinical trials." Professor Davies concluded: "We believe that OXIGON(TM), which appears to be well tolerated in humans and enters the brain...

Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile

...get indication for the vaccine is primary prevention of C. difficile infection (CDI), this trial in infected patients aims at providing early proof of concept of the vaccine approach. "Treatment of C. difficile infection includes the use of one of two antibiotics. Non-antibiotic approaches for managin...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an exist...

New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide

... trial will generate the data needed for effective product development and licensure. And as important as the PRO2000 data are in supporting the concept that a topical microbicide can prevent HIV infection, new products are needed that can increase the level of protection that was observed in the MTN s...
Other Tags
(Date:7/11/2014)... exists that cannabinoid receptor type 1 can ... influx, and reduce neurotransmitter release. However, some ... can increase extracellular Ca2+ influx and increase ... team, Tongji Hospital Affiliated to Tongji Medical ... China used whole cell voltage-clamp and calcium ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... 2014 Fadhits.com is popular among worldwide ... are extremely beautiful. Recently, the company has announced its ... 2014. What’s more, all these outfits are available at ... , Additionally, the supplier is now offering similar discounts ... dresses, it has many other designs for sale, including ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
Other Contents